There is limited experience of overdose with TREZILENT in clinical trials. In the clinical studies, TREZILENT was administered at doses up to 450 mg once daily.
In cases where accidental overdosage of TREZILENT was reported in the clinical studies, the adverse reactions associated with the overdose were consistent with the known safety profile of TREZILENT and included hyperglycemia, nausea, asthenia, and rash.
Initiate general symptomatic and supportive measures in all cases of overdosage where necessary. There is no known antidote for TREZILENT.